MeSH term
Frequency | Condition_Probility | *Acid Anhydride Hydrolases | 59 | 25.0 |
Animals | 24 | 0.0 |
CHO Cells | 3 | 0.0 |
Carcinoma, Non-Small-Cell Lung/genetics | 3 | 15.0 |
Chromosome Fragile Sites | 54 | 40.0 |
Chromosome Fragility/*genetics | 10 | 58.0 |
Chromosome Mapping | 22 | 0.0 |
Chromosomes, Human, Pair 3/*genetics | 12 | 5.0 |
Female | 36 | 0.0 |
Gene Deletion | 9 | 0.0 |
Hamsters | 6 | 0.0 |
Humans | 106 | 0.0 |
Neoplasm Proteins/*genetics | 19 | 1.0 |
Neoplasms/*genetics | 9 | 3.0 |
Research Support, U.S. Gov't, P.H.S. | 59 | 0.0 |
Stomach Neoplasms/genetics | 2 | 8.0 |
Tumor Cells, Cultured | 18 | 0.0 |
Adult | 15 | 0.0 |
Aged | 13 | 0.0 |
Chromosome Deletion | 8 | 1.0 |
*Gene Expression Regulation, Neoplastic | 5 | 0.0 |
Loss of Heterozygosity/genetics | 2 | 1.0 |
Middle Aged | 17 | 0.0 |
Carrier Proteins/*genetics | 2 | 0.0 |
Cells, Cultured | 8 | 0.0 |
Chromosomes, Artificial, Yeast/genetics | 3 | 2.0 |
Comparative Study | 6 | 0.0 |
Exons/genetics | 4 | 0.0 |
Genetic Markers/genetics | 2 | 0.0 |
Mice | 15 | 0.0 |
Research Support, Non-U.S. Gov't | 62 | 0.0 |
Base Sequence | 18 | 0.0 |
Cell Transformation, Neoplastic/genetics | 5 | 1.0 |
DNA Mutational Analysis | 5 | 0.0 |
Gene Expression | 4 | 0.0 |
Genetic Markers | 10 | 0.0 |
*Loss of Heterozygosity | 7 | 1.0 |
Lymphatic Metastasis | 4 | 0.0 |
Microsatellite Repeats/*genetics | 2 | 0.0 |
Molecular Sequence Data | 24 | 0.0 |
Polymorphism, Genetic | 2 | 0.0 |
RNA, Messenger/genetics | 3 | 0.0 |
RNA, Neoplasm/genetics | 3 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 8 | 0.0 |
Alleles | 7 | 0.0 |
Apoptosis/genetics | 3 | 1.0 |
Cell Transformation, Neoplastic/*genetics | 2 | 1.0 |
Chromosome Breakage | 5 | 6.0 |
Chromosomes, Human, Pair 3/*genetics/ultrastructure | 2 | 20.0 |
Conserved Sequence | 2 | 0.0 |
*Genes, Tumor Suppressor | 12 | 1.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Kidney Neoplasms/genetics | 3 | 4.0 |
Mice, Knockout | 3 | 0.0 |
Recombination, Genetic | 3 | 0.0 |
Translocation, Genetic | 5 | 0.0 |
English Abstract | 3 | 0.0 |
Lung Neoplasms/*genetics | 3 | 1.0 |
RNA, Messenger/analysis | 3 | 0.0 |
*Gene Therapy | 2 | 0.0 |
Immunohistochemistry | 4 | 0.0 |
Neoplasm Proteins/*genetics/metabolism | 4 | 2.0 |
Transfection | 4 | 0.0 |
Chromosome Mapping/methods | 2 | 1.0 |
Esophageal Neoplasms/genetics | 2 | 18.0 |
Homozygote | 5 | 0.0 |
Male | 18 | 0.0 |
Aged, 80 and over | 7 | 0.0 |
Disease Progression | 4 | 0.0 |
Neoplasm Invasiveness | 3 | 0.0 |
Protein p53/*biosynthesis | 2 | 1.0 |
Retrospective Studies | 2 | 0.0 |
Disease Models, Animal | 2 | 0.0 |
Genes, Tumor Suppressor/genetics | 2 | 1.0 |
*Neoplasm Proteins | 24 | 3.0 |
Proteins/*genetics | 30 | 1.0 |
*Chromosome Fragility | 41 | 33.0 |
Exons | 5 | 0.0 |
Polymerase Chain Reaction | 17 | 0.0 |
Repetitive Sequences, Nucleic Acid | 4 | 0.0 |
*Chromosomes, Human, Pair 3 | 20 | 5.0 |
DNA Damage | 2 | 0.0 |
Transcription, Genetic | 5 | 0.0 |
DNA Replication/genetics | 2 | 3.0 |
Heterozygote | 7 | 0.0 |
In Situ Hybridization, Fluorescence | 12 | 0.0 |
Sequence Tagged Sites | 2 | 0.0 |
Time Factors | 3 | 0.0 |
Adenocarcinoma/*genetics | 3 | 2.0 |
Amino Acid Sequence | 6 | 0.0 |
Chromosome Breakage/*genetics | 2 | 3.0 |
Chromosomes, Human, Pair 16/genetics | 2 | 2.0 |
Esophageal Neoplasms/*genetics | 2 | 2.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
Translocation, Genetic/*genetics | 3 | 1.0 |
DNA, Neoplasm/analysis | 2 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
Ploidies | 2 | 0.0 |
Protein p53/metabolism | 2 | 0.0 |
Survival Rate | 3 | 0.0 |
DNA, Viral/analysis | 2 | 0.0 |
*Gene Deletion | 7 | 0.0 |
Loss of Heterozygosity | 5 | 0.0 |
Polymerase Chain Reaction/methods | 3 | 0.0 |
Adenocarcinoma/*genetics/pathology | 2 | 2.0 |
Neoplasm Staging | 4 | 0.0 |
Chromosomes, Artificial, Yeast | 2 | 0.0 |
Cloning, Molecular | 10 | 0.0 |
DNA, Neoplasm/*genetics | 4 | 1.0 |
Microsatellite Repeats | 9 | 0.0 |
Sequence Deletion | 5 | 0.0 |
Chromosomes, Human, Pair 3/genetics | 6 | 4.0 |
Microsatellite Repeats/genetics | 3 | 0.0 |
Acid Anhydride Hydrolases/*genetics | 2 | 16.0 |
Cell Line, Transformed | 2 | 0.0 |
Cell Line, Tumor | 3 | 0.0 |
Hela Cells | 3 | 0.0 |
Carcinoma, Hepatocellular/*genetics | 2 | 2.0 |
Chromosome Aberrations | 5 | 0.0 |
Chromosomes, Human, Pair 3 | 3 | 1.0 |
Liver Neoplasms/*genetics | 2 | 1.0 |
Proteins/analysis/*genetics | 2 | 6.0 |
Neoplasm Proteins/genetics | 10 | 2.0 |
Genes, Tumor Suppressor | 10 | 1.0 |
Proteins/genetics/*metabolism | 2 | 0.0 |
Prognosis | 4 | 0.0 |
Carcinoma, Small Cell/genetics | 2 | 5.0 |
*Chromosome Deletion | 5 | 0.0 |
Chromosome Fragility | 4 | 6.0 |
Gene Expression Regulation, Neoplastic | 5 | 0.0 |
Genes, Tumor Suppressor/*genetics | 3 | 0.0 |
Proteins/genetics | 5 | 0.0 |
Cell Line | 7 | 0.0 |
Mutation | 4 | 0.0 |
Protein Biosynthesis | 2 | 0.0 |
Cell Division | 2 | 0.0 |
Neoplasms/genetics | 2 | 1.0 |
DNA Primers/genetics | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 7 | 0.0 |
Gene Rearrangement | 2 | 0.0 |
*Chromosome Fragile Sites | 2 | 40.0 |
DNA Methylation | 2 | 0.0 |
Carcinoma, Renal Cell/*genetics | 9 | 9.0 |
Kidney Neoplasms/*genetics | 10 | 4.0 |
DNA, Complementary/genetics/isolation & purification | 2 | 1.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Neoplasm Proteins/genetics/*metabolism | 2 | 1.0 |
Aphidicolin/*pharmacology | 3 | 37.0 |
Clone Cells | 2 | 0.0 |
Hybrid Cells | 8 | 0.0 |
Karyotyping | 5 | 0.0 |
Aphidicolin/pharmacology | 6 | 13.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Genes, Tumor Suppressor/*physiology | 2 | 1.0 |
Polymorphism, Single-Stranded Conformational | 3 | 0.0 |
Pancreatic Neoplasms/genetics | 2 | 5.0 |
*Recombination, Genetic | 2 | 0.0 |
Sequence Analysis, DNA | 7 | 0.0 |
Blotting, Southern | 4 | 0.0 |
Chromosomes, Human, Pair 3/*ultrastructure | 3 | 37.0 |
DNA Probes | 4 | 0.0 |
DNA, Neoplasm/isolation & purification | 2 | 6.0 |
RNA, Neoplasm/isolation & purification | 2 | 6.0 |
Precancerous Conditions/*genetics | 2 | 7.0 |
Blotting, Northern | 2 | 0.0 |
Mutagenesis, Insertional | 2 | 0.0 |
Chromosomes, Human, Pair 3/drug effects/*genetics | 2 | 100.0 |
DNA/genetics | 2 | 0.0 |
Chromosome Walking | 2 | 4.0 |
Acid Anhydride Hydrolases | 3 | 50.0 |
Cell Transformation, Neoplastic | 3 | 0.0 |
DNA/*genetics | 2 | 0.0 |
DNA-Directed DNA Polymerase/antagonists & inhibitors | 2 | 28.0 |
Electrophoresis, Gel, Pulsed-Field | 2 | 0.0 |
Trinucleotide Repeats | 2 | 1.0 |
Gene Library | 2 | 0.0 |
*Translocation, Genetic | 6 | 0.0 |
Chromosome Fragile Sites/*genetics | 2 | 33.0 |
Gastrointestinal Neoplasms/*genetics | 2 | 6.0 |
*Chromosomes, Human, Pair 8 | 5 | 2.0 |
Acid Anhydride Hydrolases/*genetics/metabolism | 2 | 66.0 |
Apoptosis | 2 | 0.0 |
Chromosomes, Human, Pair 8 | 2 | 1.0 |
Metaphase | 3 | 2.0 |
Base Pair Mismatch | 2 | 1.0 |
DNA Repair | 3 | 0.0 |
Chromosome Banding | 4 | 0.0 |
Adolescent | 2 | 0.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
Aphidicolin | 2 | 22.0 |
Diterpenes/pharmacology | 2 | 7.0 |
Lymphocytes/ultrastructure | 2 | 4.0 |
Neoplasm Proteins/*metabolism | 2 | 0.0 |
Neoplasm Proteins/*biosynthesis | 2 | 2.0 |
Ligases/genetics | 2 | 5.0 |
*Ubiquitin-Protein Ligases | 2 | 0.0 |
